Overview

A Study Evaluating BAT3306 Compared With Keytruda in NSCLC Cancer Participants

Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
Comparing the PK similarity of BAT3306 and Keytruda; in NSCLC participants who were completely removed by surgery as an auxiliary treatment
Phase:
PHASE1
Details
Lead Sponsor:
Bio-Thera Solutions
Treatments:
pembrolizumab